Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations - PubMed (original) (raw)

Review

Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations

Giovanna Leoncini et al. J Nephrol. 2020 Oct.

Abstract

Diabetic kidney disease (DKD) affects approximately one-third of patients with diabetes and taking into consideration the high cardiovascular risk burden associated to this condition a multifactorial therapeutic approach is traditionally recommended, in which glucose and blood pressure control play a central role. The inhibition of renin-angiotensin-aldosterone RAAS system represent traditionally the cornerstone of DKD. Clinical outcome trials have demonstrated clinical significant benefit in slowing nephropathy progression mainly in the presence of albuminuria. Thus, international guidelines mandate their use in such patients. Given the central role of RAAS activity in the pathogenesis and progression of renal and cardiovascular damage, a more profound inhibition of the system by the use of multiple agents has been proposed in the past, especially in the presence of proteinuria, however clinical trials have failed to confirm the usefulness of this therapeutic approach. Furthermore, whether strict blood pressure control and pharmacologic RAAS inhibition entails a favorable renal outcome in non-albuminuric patients is at present unclear. This aspect is becoming an important issue in the management of DKD since nonalbuminuric DKD is currently the prevailing presenting phenotype. For these reasons it would be advisable that blood pressure management should be tailored in each subject on the basis of the renal phenotype as well as related comorbidities. This article reviews the current literature and discusses potentials and limitation of targeting the RAAS in order to provide the greatest renal protection in DKD.

Keywords: Albuminuria; Blood pressure; Diabetic kidney disease; RAAS inhibition; Renal progression.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1

Fig. 1

Natural history of diabetic kidney disease

References

    1. Thomas B. The global burden of diabetic kidney disease: time trends and gender gaps. Curr Diabetes Rep. 2019;19:18. doi: 10.1007/s11892-019-1133-6. - DOI - PubMed
    1. Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71:884–895. doi: 10.1053/j.ajkd.2017.10.026. - DOI - PubMed
    1. De Cosmo S, Rossi MC, Pellegrini F, Lucisano G, Bacci S, Gentile S, Ceriello A, Russo G, Nicolucci A, Giorda C, Viazzi F, Pontremoli R, AMD-Annals Study Group Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrol Dial Transpl. 2014;29:657–662. doi: 10.1093/ndt/gft506. - DOI - PubMed
    1. Viazzi F, Russo GT, Ceriello A, Fioretto P, Giorda C, De Cosmo S, Pontremoli R. Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals. J Nephrol. 2019;32:517–525. doi: 10.1007/s40620-018-00561-3. - DOI - PubMed
    1. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS Group Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int. 2003;63:225–232. doi: 10.1046/j.1523-1755.2003.00712.x. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources